Abstract
Accumulating evidence indicates that epigenetic events undergo deregulation in various cancer types, playing crucial roles in tumor development. Among the epigenetic factors involved in the epigenetic remodeling of chromatin, the chromodomain helicase DNA-binding protein (CHD) family frequently exhibits gain- or loss-of-function mutations in distinct cancer types. Therefore, targeting CHD remodelers holds the potential for antitumor treatment. In this review, we discuss epigenetic regulations of cancer development. We emphasize proteins in the CHD family, delving deeply into the intricate mechanisms governing their functions. Additionally, we provide an overview of current therapeutic strategies targeting CHD family members in preclinical trials. We further discuss the promising approaches that have demonstrated early signs of success in cancer treatment.
| Original language | English (US) |
|---|---|
| Article number | 108610 |
| Journal | Pharmacology and Therapeutics |
| Volume | 256 |
| DOIs | |
| State | Published - Apr 2024 |
Funding
This project is supported in part by NIH grants R01GM138407 (Kaifu Chen), R01GM125632 (Kaifu Chen), R01HL148338 (Kaifu Chen), R01HL133254 (Kaifu Chen), R01CA208257 (Qi Cao), R01CA256741 (Qi Cao) and U.S. Department of Defense grants W81XWH-17-1-0357 (Qi Cao), W81XWH-19-1-0563 (Qi Cao) and W81XWH-20-1-0504 (Qi Cao), Prostate SPORE P50CA180995 Development Research Program (Qi Cao), the Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital (Qi Cao), and R01HL155632 (Lili Zhang).
Keywords
- Cancer development
- Chromatin remodeling
- Epigenetic regulation
- Therapeutic strategies
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
